

AMENDMENTS TO THE CLAIMS

1-36. (Canceled)

37. (Currently Amended) A method of inhibiting the transcription and/or translation of a polynucleotide encoding a ~~mammalian~~ human CDC25A protein in a cell in vitro, comprising contacting said polynucleotide with an oligonucleotide that hybridizes to a nucleic acid consisting of the sequence set forth of in SEQ ID NO:1 ~~encoding a mammalian CDC25A protein, or the complement thereof of said sequence, under stringent conditions of 5-10 °C below the calculated melting temperature T_m of said sequence.~~

38. (Canceled)

39. (Currently Amended) The method of claim 38 37, wherein said ~~mammalian~~ human CDC25A has the amino acid sequence set forth in SEQ ID NO: 2.

40. (Canceled)

41. (Currently Amended) The method of claim 37, wherein said ~~mammalian~~ human CDC25A protein has endogenous tyrosine phosphatase activity.

42. (Currently Amended) The method of claim 37, wherein said ~~mammalian~~ human CDC25A protein rescues a cdc25-deficient strain of fission yeast.

43. (Previously Presented) The method of claim 37, wherein said polynucleotide is mRNA.

44. (Canceled)

45. (New) A method of inhibiting the transcription and/or translation of a polynucleotide encoding a human CDC25A protein in a cell in vitro, comprising contacting said polynucleotide with an oligonucleotide that

- (i) is complementary to the sequence set forth in SEQ ID NO: 1 or to a portion thereof; and
- (ii) hybridizes to the polynucleotide or to the complement thereof.

46. (New) The method of claim 45, wherein the polynucleotide encoding the human CDC25A protein comprises a sequence as set forth in SEQ ID NO:1.

47. (New) The method of claim 45, wherein said human CDC25A has the amino acid sequence set forth in SEQ ID NO: 2.